Introducing Revvity – Expanding the boundaries of human potential through science.
All products and services previously affiliated with Oxford Immunotec are now part of Revvity.

Study Results Demonstrate Ability Of T-SPOT®.TB To Monitor Declining Response In Subjects Receiving Anti-TB Treatment

Oxford, UK; 20 February 2008 – Oxford Immunotec Ltd., the T cell measurement company, today announced the publication of a recent study demonstrating a decline in the positivity of its T-SPOT.TB test in subjects who had been taking anti-TB therapy for a longer length of time.

In this study reported in the Journal of Infection Dheda et al investigated the response of the T-SPOT.TB assay in 33 subjects with culture confirmed TB. T-SPOT.TB was positive in 83% of the subjects who had received less than 4 months anti-TB therapy whereas only 17% of subjects who had received more than 4 months therapy were positive by the test.

These findings suggest that the response of T-SPOT.TB declines with therapy and may be a potentially useful treatment monitoring tool.

Commenting on the results, Dr Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec said, “This study provides additional evidence that the T-SPOT.TB test may have a future role to play as an additional tool in the monitoring of anti-TB treatments. Treatment monitoring in TB infection is particularly important since the treatment period is typically six months or longer.”